These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 17062705

  • 1. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [Abstract] [Full Text] [Related]

  • 2. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb 15; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 3. Cellular and molecular mechanisms of action of bisphosphonates.
    Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC.
    Cancer; 2000 Jun 15; 88(12 Suppl):2961-78. PubMed ID: 10898340
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
    Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP.
    J Bone Miner Res; 2006 May 15; 21(5):684-94. PubMed ID: 16734383
    [Abstract] [Full Text] [Related]

  • 5. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
    Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ.
    Bone; 2005 Sep 15; 37(3):349-58. PubMed ID: 16006204
    [Abstract] [Full Text] [Related]

  • 6. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug 15; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonates: from bench to bedside.
    Russell RG.
    Ann N Y Acad Sci; 2006 Apr 15; 1068():367-401. PubMed ID: 16831938
    [Abstract] [Full Text] [Related]

  • 8. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S, Kamiya S, Ono K.
    Clin Calcium; 2005 May 15; 15(5):819-24. PubMed ID: 15876745
    [Abstract] [Full Text] [Related]

  • 9. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
    Thompson K, Dunford JE, Ebetino FH, Rogers MJ.
    Biochem Biophys Res Commun; 2002 Jan 18; 290(2):869-73. PubMed ID: 11785983
    [Abstract] [Full Text] [Related]

  • 10. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 11. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA, Rodan GA.
    Mini Rev Med Chem; 2004 Sep 01; 4(7):711-9. PubMed ID: 15379639
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates: preclinical review.
    Green JR.
    Oncologist; 2004 Sep 01; 9 Suppl 4():3-13. PubMed ID: 15459425
    [Abstract] [Full Text] [Related]

  • 13. Recent advances in understanding the mechanism of action of bisphosphonates.
    Coxon FP, Thompson K, Rogers MJ.
    Curr Opin Pharmacol; 2006 Jun 01; 6(3):307-12. PubMed ID: 16650801
    [Abstract] [Full Text] [Related]

  • 14. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G.
    Arch Biochem Biophys; 2000 Jan 01; 373(1):231-41. PubMed ID: 10620343
    [Abstract] [Full Text] [Related]

  • 15. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
    Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH.
    Bone; 2006 May 01; 38(5):617-27. PubMed ID: 16046206
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG, Rogers MJ.
    Bone; 1999 Jul 01; 25(1):97-106. PubMed ID: 10423031
    [Abstract] [Full Text] [Related]

  • 17. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
    Rogers MJ.
    Calcif Tissue Int; 2004 Dec 01; 75(6):451-61. PubMed ID: 15332174
    [Abstract] [Full Text] [Related]

  • 18. [Mechanisms of action in bisphosphonates].
    Hoshino H, Yamazaki K.
    Clin Calcium; 2005 Jul 01; 15(7):88-92. PubMed ID: 15995302
    [Abstract] [Full Text] [Related]

  • 19. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
    Rogers MJ, Xiong X, Brown RJ, Watts DJ, Russell RG, Bayless AV, Ebetino FH.
    Mol Pharmacol; 1995 Feb 01; 47(2):398-402. PubMed ID: 7870050
    [Abstract] [Full Text] [Related]

  • 20. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
    Plotkin LI, Manolagas SC, Bellido T.
    Bone; 2006 Sep 01; 39(3):443-52. PubMed ID: 16627025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.